Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Toxicol Sci ; 42(3): 343-348, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28496040

RESUMEN

Evidence has been presented for auto-induced human cytochrome P450 3A enzyme involvement in the teratogenicity and clinical outcome of thalidomide due to oxidation to 5-hydroxythalidomide and subsequent metabolic activation in livers. In this study, more relevant human placenta preparations and placental BeWo cells showed low but detectable P450 3A4/5 mRNA expression and drug oxidation activities. Human placental microsomal fractions from three subjects showed detectable midazolam 1´- and 4-hydroxylation and thalidomide 5-hydroxylation activities. Human placental BeWo cells, cultured in the recommended media, also indicated detectable midazolam 1´- and 4-hydroxylation and thalidomide 5-hydroxylation activities. To reduce any masking effects by endogenous hormones used in the recommended media, induction of P450 3A4/5 mRNA and oxidation activities were measured in placental BeWo cells cultured with a modified medium containing 5% charcoal-stripped fetal bovine serum. Thalidomide significantly induced P450 3A4/5, 2B6, and pregnane X receptor (PXR) mRNA levels 2 to 3-fold, but rifampicin only enhanced P450 3A5 and PXR mRNA under the modified media conditions. Under these modified conditions, thalidomide also significantly induced midazolam 1´-hydroxylation and thalidomide 5-hydroxylaion activities 3-fold but not bupropion hydroxylation activity. Taken together, activation of thalidomide to 5-hydroxythalidomide with autoinduction of P450 3A enzymes in human placentas, as well as livers, is suggested in vivo.


Asunto(s)
Citocromo P-450 CYP3A/biosíntesis , Placenta/enzimología , Talidomida/toxicidad , Células Cultivadas , Inducción Enzimática/efectos de los fármacos , Femenino , Humanos , Hígado/metabolismo , Oxidación-Reducción , Placenta/citología , Embarazo , Receptor X de Pregnano , ARN Mensajero/metabolismo , Receptores de Esteroides/genética , Receptores de Esteroides/metabolismo , Rifampin/toxicidad , Talidomida/análogos & derivados , Talidomida/metabolismo
2.
Yonago Acta Med ; 60(4): 241-245, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-29434494

RESUMEN

Schizencephaly and porencephaly are extremely rare types of cortical dysplasia. Case 1: Prenatal magnetic resonance imaging (MRI) showed wide clefts in the frontal and parietal lobes bilaterally. On postnatal day 3, MRI T2-weighted images showed multiple hypointensities in the clefts and ventricular walls, suggestive of hemosiderosis secondary to intracranial hemorrhage. Case 2: Prenatal MRI showed bilateral cleft and cyst formation in the fetal cerebrum, as well as calcification and hemosiderosis indicative of past hemorrhage. T2-weighted images showed hypointensities in the same regions as the calcification, corresponding with hemosiderosis due to intracranial hemorrhage on postnatal day 10. Thus, prenatal MRI was useful for diagnosing schizencephaly and porencephaly. Schizencephaly and porencephaly were thought to be due to fetal intracranial hemorrhage, which, in the porencephaly case, may have been related to a mutation of COL4A1.

3.
Eur J Obstet Gynecol Reprod Biol ; 191: 116-20, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26115056

RESUMEN

OBJECTIVES: Low dose oral contraceptive pills (OCPs) that contain synthetic estrogen and progestin are often used to relieve chronic pelvic pain associated with endometriosis. We sought to evaluate the efficacy of drospirenone/ethinylestradiol (DRSP/EE) with low-dose estrogen in treating endometrioma. STUDY DESIGN: A prospective clinical study in six hospitals and one clinic in Japan was conducted. Forty-nine 23- to 45-year-old patients who suffered from endometriosis-associated dysmenorrhea were included in the study. The primary endpoint was the change in size of ovarian endometrioma as measured by transvaginal ultrasonography. The secondary endpoint was the change in dysmenorrhea as evaluated by VAS (visual analog scale) scores before treatment and at 3 and 6 cycles of treatment. In addition, serum CA125, anti-mullerian hormone (AMH), interleukin (IL)-6, and IL-8 were evaluated after 6 cycles of treatment. RESULTS: The maximum diameter and volume of the ovarian endometrioma significantly decreased after 3 and 6 cycles compared with pretreatment. VAS scores of dysmenorrhea pain were also reduced after 1, 3 and 6 cycles. A significant correlation between the reduced size of the endometrioma and the decline of VAS scores was found. The levels of serum CA125 and AMH concentration were decreased after 6 cycles. No significant changes were observed in serum IL-6 and IL-8. CONCLUSION: Low dose DRSP/EE therapy is a promising treatment not only to reduce the size of endometrioma but also for dysmenorrhea.


Asunto(s)
Androstenos/uso terapéutico , Anticonceptivos Orales Combinados/uso terapéutico , Anticonceptivos Hormonales Orales/uso terapéutico , Dismenorrea/prevención & control , Endometriosis/tratamiento farmacológico , Etinilestradiol/uso terapéutico , Enfermedades del Ovario/tratamiento farmacológico , Adulto , Androstenos/administración & dosificación , Biomarcadores/sangre , Anticonceptivos Orales Combinados/administración & dosificación , Anticonceptivos Hormonales Orales/administración & dosificación , Dismenorrea/etiología , Endometriosis/sangre , Endometriosis/diagnóstico por imagen , Endometriosis/fisiopatología , Estrógenos/administración & dosificación , Estrógenos/uso terapéutico , Etinilestradiol/administración & dosificación , Femenino , Humanos , Japón , Persona de Mediana Edad , Tamaño de los Órganos/efectos de los fármacos , Enfermedades del Ovario/sangre , Enfermedades del Ovario/diagnóstico por imagen , Enfermedades del Ovario/fisiopatología , Reserva Ovárica/efectos de los fármacos , Ovario/diagnóstico por imagen , Ovario/efectos de los fármacos , Ovario/patología , Dimensión del Dolor/efectos de los fármacos , Congéneres de la Progesterona/administración & dosificación , Congéneres de la Progesterona/uso terapéutico , Ultrasonografía , Adulto Joven
4.
J Ultrasound Med ; 30(4): 529-45, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21460154

RESUMEN

The management of growth-restricted fetuses requires accurate diagnosis to optimize the timing of delivery. Doppler velocimetry is the only noninvasive method for assessing the fetoplacental hemodynamic status. This review will give a critical overview of the current knowledge on fetal venous blood flow in pregnancies complicated by in-trauterine growth-restricted fetuses. Adaptation of the circulation in intrauterine growth-restricted fetuses is described. Normal and abnormal venous Doppler waveforms are presented. Correlations of abnormal waveforms with the presence of acidemia and perinatal outcomes are emphasized. Limitations of venous Doppler velocimetry for optimizing the time for delivery and the perinatal outcome are also presented.


Asunto(s)
Retardo del Crecimiento Fetal/diagnóstico por imagen , Retardo del Crecimiento Fetal/fisiopatología , Ultrasonografía Doppler/métodos , Ultrasonografía Prenatal/métodos , Arterias Umbilicales/diagnóstico por imagen , Arterias Umbilicales/fisiopatología , Animales , Velocidad del Flujo Sanguíneo , Femenino , Humanos , Placenta/irrigación sanguínea , Placenta/diagnóstico por imagen , Valor Predictivo de las Pruebas , Embarazo , Resultado del Embarazo , Reología/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...